Tag: rheumatoid arthritis
1. Upadacitinib was superior to abatacept in achieving remission at 12 weeks for patients with rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs (DMARDs).
2. Upadacitinib was associated with more severe adverse events compared to abatacept.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Abatacept treats rheumatoid arthritis by inhibiting T-cell proliferation and...
1. Tumor necrosis factor inhibitor exposure in patients with autoimmune disease, particularly rheumatoid arthritis, was associated with increased risk of inflammatory central nervous system events.
Evidence Rating Level: 2 (Good)
The U.S. Food and Drug Administration has approved five tumor necrosis factor (TNF) inhibitors as immunotherapies for autoimmune diseases: etanercept, adalimumab, infliximab,...
1. Tumor necrosis factor inhibitor exposure in patients with autoimmune disease, particularly rheumatoid arthritis, was associated with increased risk of inflammatory central nervous system events.
Evidence Rating Level: 2 (Good)
The U.S. Food and Drug Administration has approved five tumor necrosis factor (TNF) inhibitors as immunotherapies for autoimmune diseases: etanercept, adalimumab, infliximab,...
Tumour necrosis factor (TNF) alpha inhibitors have greatly improved disease control and quality of life in patients affected by rheumatoid arthritis; however, up to one third of patients fail to respond to these agents. Alternative non-TNF targeted biologics have also emerged, including rituximab, abatacept and tocilizumab. In this prospective...
1. Biologic therapy had minimal additional benefits for patients compared to triple therapy.
2. When used as a first-line therapy, triple therapy resulted in significantly lower drug costs than biologic therapy.
Evidence Rating Level: 2 (Good)
Study Rundown: Guidelines currently recommend treating rheumatoid arthritis patients with biologic drugs, such as etanercept, following...
Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer
First line treatment for patients with advanced, non-small cell lung cancers that overexpress epidermal growth factor receptor (EGFR) is a tyrosine kinase inhibitor to that receptor(EGFR-TKI). However, a common T790M mutation has been identified that reduces TKI binding, reduces drug efficacy and...
1. Baricitinib, an oral, once-daily inhibitor of JAK1 and JAK2, has shown promise in the treatment of rheumatoid arthritis (RA).
2. In this randomized controlled trial, baricitinib was superior to injectable adalimumab and placebo, in the amelioration of prespecified RA-related symptoms and radiologic outcomes after 12 weeks of follow-up.
Evidence Rating...
1. The addition of a non-TNF-targeted biologic therapy is superior to the addition of an anti-TNF biologic therapy in patients with rheumatoid arthritis that is not well controlled with a first-line anti-TNF medication.
2. There was no difference in serious adverse events or infections between the two classes of therapeutics.
Evidence...
1. Patients who developed rheumatoid arthritis (RA) were less likely to have had a gastrointestinal (GI) or genitourinary (GU) infection within the previous two years.
2. Recent gastroenteritis was linked with a lowere RA risk in patients with both the presence and absence of anti-citrullinated protein antibodies (ACPA).
Evidence Rating...